Allegis Investment Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Allegis Investment Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-222	Closed	-$11K	–	708
2015 Q4	$11K	Buy	+222	New	+$11K	0.01%	648

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TAM

Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return

HBT

Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Allegis Investment Advisors's PBE Position: Q1 2016 in Review

Allegis Investment Advisors sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2016, closing a stake of 222 shares — an estimated $11K sold.

Allegis Investment Advisors first reported a position in PBE in Q4 2015 and held it in 1 quarter. The position peaked at $11K in Q4 2015. 71 funds tracked by Wall St. Rank hold PBE as of Q1 2016.

Allegis Investment Advisors reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2016 after selling out during the quarter.
Allegis Investment Advisors sold 222 Invesco Biotechnology & Genome ETF shares in Q1 2016, an estimated $11K.
Allegis Investment Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q4 2015 and held it in 1 quarter.
Allegis Investment Advisors's Invesco Biotechnology & Genome ETF position peaked at $11K in Q4 2015.
71 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2016.

Based on Allegis Investment Advisors's 13F filing for Q1 2016, filed 9 May 2016.